Investors and consultants in the space said that they have seen rising enthusiasm among investors as recent funding rounds outpace prior hauls.

If the initiative proceeds as planned, it will mark a pivotal shift in the regulatory landscape, introducing both efficiencies and novel ...

AI adoption in the corporate world is not a sprint—it’s a strategic journey where early experimentation gives way to ...

The FDA and NIH recently announced plans to phase out animal testing requirements for some therapies. While organoid and AI ...

The department’s chief data and artificial intelligence office and members of the Data & AI Board will oversee the new center.

The Administration for Strategic Preparedness and Response May 15 announced it is launching four pharmaceutical manufacturing ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

AI adoption in pharma can be slow, but failing to scale these new tools across your organization is a missed opportunity.

The unintentional theme of today’s issue is the struggle for control over how we implement AI in the U.S. On one side, where ...

FDA seeking 'aggressive' adoption of AI . The FDA announced an "aggressive timeline" to deploy artificial intelligence ...